Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Roberto Orlandi"'
Autor:
Arcangelo Russo, Gabriele Cortina, Vincenzo Condello, Marco Collarile, Roberto Orlandi, Riccardo Gianoli, Emanuele Giuliani, Vincenzo Madonna
Publikováno v:
Journal of Experimental Orthopaedics, Vol 10, Iss 1, Pp n/a-n/a (2023)
Abstract Purpose Among the conservative strategies to manage patients with symptomatic knee osteoarthritis (OA), an innovative approach exploiting the regenerative capability of adipose tissue and its resident MSCs (Mesenchymal Stem Cells or Medicina
Externí odkaz:
https://doaj.org/article/e1bd8e4f9dd44326b3c1d6510256baaf
Autor:
Vincenzo De Leo, Carlo Setacci, Roberto Orlandi, Felice Petraglia, Donatella Crippa, Antonio La Marca
Publikováno v:
Maturitas. 46:219-224
Ojectives: The incidence of cardiovascular disease (CVD) increases dramatically with the loss of ovarian function. Observational studies indicate that the risk of CVD may be reduced by up to 50% in postmenopausal women who take estrogen replacement t
Publikováno v:
Maturitas. 39:125-132
In order to assess the effects of menopause and hormonal replacement therapy (HRT) on body weight and body fat distribution (determined by dual energy X-ray), early postmenopausal women were given either oral calcium (500 mg/day, control group, n=13)
Autor:
Anna Maria Paoletti, Marisa Orrù, Donatella Crippa, Maria Del Zompo, Gian Benedetto Melis, Marina Mannias, Stefano Floris, Roberto Orlandi
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 86:608-612
The psychological symptoms assessed with a validated psychometric scale, SCL-90, were significantly higher in postmenopausal women (PMW; 60 subjects) than in premenopausal women (20 subjects). In the same PMW, the activity of the dopaminergic system,
Autor:
A Spinetti, L. Piaggesi, Marco Gambacciani, Barbara Cappagli, Roberto Orlandi, Carlo Weiss, Andrea R. Genazzani, M. Ciaponi
Postmenopausal women were randomly given either oral calcium (500 mg/day, control group, n = 12) or a combination of estradiol valerate (EV, 2 mg/day for 21 days) with cyproterone acetate (CPA, 1 mg/day in the last 10 days of the treatment cycle, n =
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b342c6e79a10ba4b2f711a4078925588
http://hdl.handle.net/11568/30129
http://hdl.handle.net/11568/30129
Autor:
L. Zanotti, Roberto Orlandi, P. Albertazzi, Antonio Farina, Gioacchino Mollica, C. Campobasso, Francesco Pansini, Gloria Bonaccorsi, Bruno Bagni
Publikováno v:
Scopus-Elsevier
Autor:
Roberto Orlandi
Publikováno v:
Filologija
Issue 3
Issue 3